Pharmacological HIF-1 activation upregulates extracellular vesicle production synergistically with adiponectin through transcriptional induction and protein stabilization of T-cadherin

Kohei Fujii,Yuya Fujishima,Shunbun Kita,Keitaro Kawada,Keita Fukuoka,Taka-aki Sakaue,Tomonori Okita,Emi Kawada-Horitani,Hirofumi Nagao,Shiro Fukuda,Norikazu Maeda,Hitoshi Nishizawa,Iichiro Shimomura

DOI: https://doi.org/10.1038/s41598-024-51935-6

IF: 4.6

2024-02-15

Scientific Reports

Abstract:Pharmacological activation of hypoxia-inducible factor 1 (HIF-1), a hypoxia-responsive transcription factor, has attracted increasing attention due to its efficacy not only in renal anemia but also in various disease models. Our study demonstrated that a HIF-1 activator enhanced extracellular vesicle (EV) production from cultured endothelial cells synergistically with adiponectin, an adipocyte-derived factor, through both transcriptional induction and posttranscriptional stabilization of an adiponectin binding partner, T-cadherin. Increased EV levels were observed in wild-type mice but not in T-cadherin null mice after consecutive administration of roxadustat. Adiponectin- and T-cadherin-dependent increased EV production may be involved in the pleiotropic effects of HIF-1 activators.

multidisciplinary sciences

What problem does this paper attempt to address?

The problem that this paper attempts to solve is to enhance the production of extracellular vesicles (EVs) through pharmacological activation of hypoxia - inducible factor 1 (HIF - 1), especially to explore whether this process can be achieved through the synergistic effect of transcriptional induction and protein stabilization of T - cadherin and adipocyte - derived factor adiponectin. Specifically, the research focuses on the following points:

1. **Effect of pharmacological HIF - 1 activation on T - cadherin expression**: The researchers found that by using HIF - 1 activators (such as roxadustat), the mRNA and protein levels of T - cadherin in endothelial cells can be significantly increased. This indicates that HIF - 1 activation not only promotes the expression of T - cadherin at the transcriptional level but also stabilizes the T - cadherin protein at the post - translational level.

2. **Effect of the synergistic action of HIF - 1 activation and adiponectin on EV production**: The researchers further found that the synergistic action of HIF - 1 activators and adiponectin can significantly increase the production of extracellular vesicles. This synergistic effect depends on the expression of T - cadherin, because when T - cadherin is knocked down, even in the presence of adiponectin, the production of EVs will not increase.

3. **HIF - 1 activation stabilizes T - cadherin protein by down - regulating ADAM12**: Through RNA - seq analysis, the researchers found that the HIF - 1 activator roxadustat significantly down - regulates the expression of ADAM12, and ADAM12 is a known metalloproteinase that can cleave T - cadherin. Therefore, HIF - 1 activation reduces the degradation of T - cadherin by down - regulating ADAM12, thereby stabilizing the T - cadherin protein.

4. **In vivo experimental verification**: The researchers conducted experiments in mice and found that continuous administration of roxadustat for three days can significantly increase the number of EVs in the plasma of wild - type mice, while this effect is not observed in T - cadherin - deficient mice. This further confirms the crucial role of T - cadherin in HIF - 1 activator - induced EV production.

In summary, the main objective of this paper is to explore how HIF - 1 activators enhance the production of extracellular vesicles by regulating the expression and stability of T - cadherin and through the synergistic action with adiponectin, which may provide new strategies for the treatment of various diseases.